ClinicalTrials.gg
RecruitingNCT06305000Updated Nov 19, 2026

Impact of Keratinized Mucosa Augmentation on Treatment Outcomes of Peri-implant Mucositis

An interventional study of Non-surgical treatment and Free gingival graft in Peri-implant Mucositis, sponsored by Biruni University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Biruni University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 7 months later.
Updated Nov 19, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
48
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Mucositis with a site in Turkey — 4 open to participants now, 5 under way, none of them phase 3. Mucositis · Turkey.

Started
2024
with 2 others
No phase
8 of 13
3 open now
Registered
4th of 13
by date
Lead sponsor
1 of 13
Biruni University

Among the 13 studies in Mucositis with a site in Turkey, this one is one of 3 that started in 2024, is one of 8 with no phase, and was the 4th registered.

Mucositis

265 studies on the registry are indexed under Mucositis; 34 are open to participants now.

Browse Mucositis studies →

Open to participants now

4 of the 13 studies in Mucositis with a site in Turkey are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 21 Mucositis studies recruiting now, 13 (62%) set no upper age limit and 7 (33%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Mucositis with a site in Turkey, or all of them as a file.
02

Study summary

This study aims to observe the effects of keratinized mucosa width on peri-implant tissues by evaluating clinical and biochemical parameters. The main question it aims to answer is:

Would increasing the width of the keratinized mucosa with free gingival graft (FGG) in peri-implant mucositis be beneficial in terms of clinical periodontal parameters and peri-implant crevicular fluid levels of inflammatory cytokines compared to non-surgical therapy alone?

Our study consists of 4 groups:

Peri-implant healthy group with sufficient keratinized mucosa (≥ 2mm) (n=16), peri-implant mucositis group with sufficient keratinized mucosa (n=16), peri-implant mucositis group with insufficient keratinized mucosa (\< 2mm) receiving only non-surgical treatment (n=16), peri-implant mucositis group with insufficient keratinized mucosa receiving FGG in addition to non-surgical treatment (n=16). Clinical and biochemical measurements will be recorded at the baseline, 1st month, 4th month and 7th month of the study. Peri-implant crevicular fluid samples will be collected at baseline, 1st month, 4th month and 7th month. IL-1β, RANKL, OPG levels, and RANKL/OPG ratio will be analyzed from collected samples.

Researchers will evaluate the possible benefits of FGG application in addition to non-surgical therapy by comparing the biochemical and clinical changes in areas with and without FGG application in the treatment of peri-implant mucositis.

03

Conditions studied

  • Peri-implant Mucositis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individual dental implants with a fixed prosthetic restoration that has been functional for at least 1 year
  • No systemic disease and medication use that may affect periodontal or peri-implanter tissues
  • Not receiving periodontal treatment in the last 6 months
  • Volunteering to participate in the study

Exclusion criteria

Exclusion Criteria:

  • Prosthetic restorations with an excessive contour which do not allow peri-implant pocket measurement
  • Being pregnant or breastfeeding,
  • and/or inflammatory diseases of the oral cavity,
  • Active periodontal disease
  • Smokers (≥ 10 cigarettes per day)
  • Improperly positioned implants
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
48 participants (estimated)

Study arms

  • No intervention
    Peri-implant healthy group with sufficient keratinized mucosa (≥ 2mm)
  • Experimental
    Peri-implant mucositis group with sufficient keratinized mucosa (≥ 2mm)

    Only non-surgical therapy will apply

    Procedure: Non-surgical treatment

  • Experimental
    Peri-implant mucositis group with insufficient keratinized mucosa (< 2mm) receiving FGG

    Free gingival graft will apply following non-surgical therapy

    Procedure: Non-surgical treatment · Procedure: Free gingival graft

Interventions

  • ProcedureNon-surgical treatment

    Non-surgical treatment consists of oral hygiene instructions, full mouth supragingival scaling using titanium hand instruments, ultrasonic devices, and subgingival debridement under local anesthesia with titanium curettes and ultrasonic instruments in a single appointment.

  • ProcedureFree gingival graft

    After adequate local anesthesia is achieved. A horizontal incision is placed mucogingival junction level to prepare the recipient bed. A split-thickness flap is raised without disturbing the periosteum. FGG is obtained from the palate, extending from the mesial surface of the second premolar to the middle of the first molar. The graft is shaped and stitched on the recipient surface.

06

What researchers measure

Primary outcomes

  1. Inflammatory parameter levels in peri-implant crevicular fluid

    Peri-implant crevicular fluid samples will be collected from 3 sites (mesiobuccal, buccal, distobuccal) of the implants using methylcellulose strips PerioPaper® (Oralflow Inc., Smithtown, NY, USA) gently placed into the cleansed and dried pocket for 30 sec. Interleukin-1beta, RANKL and OPG levels and RANKL/ OPG ratio will be evaluated.

    Time frame: Baseline (prior to therapy)

  2. Inflammatory parameter levels in peri-implant crevicular fluid

    Peri-implant crevicular fluid samples will be collected from 3 sites (mesiobuccal, buccal, distobuccal) of the implants using methylcellulose strips PerioPaper® (Oralflow Inc., Smithtown, NY, USA) gently placed into the cleansed and dried pocket for 30 sec. Interleukin-1beta, RANKL and OPG levels and RANKL/ OPG ratio will be evaluated.

    Time frame: 1st month

  3. Inflammatory parameter levels in peri-implant crevicular fluid

    Peri-implant crevicular fluid samples will be collected from 3 sites (mesiobuccal, buccal, distobuccal) of the implants using methylcellulose strips PerioPaper® (Oralflow Inc., Smithtown, NY, USA) gently placed into the cleansed and dried pocket for 30 sec. Interleukin-1beta, RANKL and OPG levels and RANKL/ OPG ratio will be evaluated.

    Time frame: 4th month

  4. Inflammatory parameter levels in peri-implant crevicular fluid

    Peri-implant crevicular fluid samples will be collected from 3 sites (mesiobuccal, buccal, distobuccal) of the implants using methylcellulose strips PerioPaper® (Oralflow Inc., Smithtown, NY, USA) gently placed into the cleansed and dried pocket for 30 sec. Interleukin-1beta, RANKL and OPG levels and RANKL/ OPG ratio will be evaluated.

    Time frame: 7th month

Secondary outcomes

  1. Plaque index (Silness & Löe, 1964)

    0: Absence of microbial plaque 1. Thin plaque layer at the mucosal margin, only detectable by scraping with a probe 2. Moderate layer of plaque in the along the mucosal margin; interdental spaces free, but plaque is visible to naked eye 3. Abundant plaque along with the mucosal margin; interdental places filled with plaque

    Time frame: Baseline (prior to therapy)

  2. Plaque index (Silness & Löe, 1964)

    Plaque index (Silness \& Löe, 1964): 0: Absence of microbial plaque 1. Thin plaque layer at the mucosal margin, only detectable by scraping with a probe 2. Moderate layer of plaque in the along the mucosal margin; interdental spaces free, but plaque is visible to naked eye 3. Abundant plaque along with the mucosal margin; interdental places filled with plaque

    Time frame: 1st month

  3. Plaque index (Silness & Löe, 1964)

    0: Absence of microbial plaque 1. Thin plaque layer at the mucosal margin, only detectable by scraping with a probe 2. Moderate layer of plaque in the along the mucosal margin; interdental spaces free, but plaque is visible to naked eye 3. Abundant plaque along with the mucosal margin; interdental places filled with plaque

    Time frame: 4th month

  4. Plaque index (Silness & Löe, 1964)

    0: Absence of microbial plaque 1. Thin plaque layer at the mucosal margin, only detectable by scraping with a probe 2. Moderate layer of plaque in the along the mucosal margin; interdental spaces free, but plaque is visible to naked eye 3. Abundant plaque along with the mucosal margin; interdental places filled with plaque

    Time frame: 7th month

  5. Gingival Index ( Löe & Silness,1963)

    0: normal gingiva 1. mild inflammation - slight change in color and slight edema but no bleeding on probing 2. moderate inflammation - redness, edema and glazing, bleeding on probing 3. severe inflammation - marked redness and edema, ulceration with tendency to spontaneous bleeding

    Time frame: Baseline (prior to therapy)

  6. Gingival Index ( Löe & Silness,1963)

    0: normal gingiva 1. mild inflammation - slight change in color and slight edema but no bleeding on probing 2. moderate inflammation - redness, edema and glazing, bleeding on probing 3. severe inflammation - marked redness and edema, ulceration with tendency to spontaneous bleeding

    Time frame: 1st month

  7. Gingival Index ( Löe & Silness,1963)

    0: normal gingiva 1. mild inflammation - slight change in color and slight edema but no bleeding on probing 2. moderate inflammation - redness, edema and glazing, bleeding on probing 3. severe inflammation - marked redness and edema, ulceration with tendency to spontaneous bleeding

    Time frame: 4th month

  8. Gingival Index ( Löe & Silness,1963)

    0: normal gingiva 1. mild inflammation - slight change in color and slight edema but no bleeding on probing 2. moderate inflammation - redness, edema and glazing, bleeding on probing 3. severe inflammation - marked redness and edema, ulceration with tendency to spontaneous bleeding

    Time frame: 7th month

  9. Bleeding on probing (Ainamo & Bay 1975)

    Bleeding on probing A bleeding-on-probing percentage score assessed as the proportion of bleeding sites (dichotomous yes/no evaluation) when stimulated by a standardized manual probe with a controlled (\~25 g) force to the bottom of the sulcus/pocket at six sites (mesiobuccal, buccal, distobuccal, mesiolingual, lingual, distolingual) on all present teeth/ implants.

    Time frame: Baseline (prior to therapy)

  10. Bleeding on probing (Ainamo & Bay 1975)

    Bleeding on probing A bleeding-on-probing percentage score assessed as the proportion of bleeding sites (dichotomous yes/no evaluation) when stimulated by a standardized manual probe with a controlled (\~25 g) force to the bottom of the sulcus/pocket at six sites (mesiobuccal, buccal, distobuccal, mesiolingual, lingual, distolingual) on all present teeth/ implants.

    Time frame: 1st month

  11. Bleeding on probing (Ainamo & Bay 1975)

    Bleeding on probing A bleeding-on-probing percentage score assessed as the proportion of bleeding sites (dichotomous yes/no evaluation) when stimulated by a standardized manual probe with a controlled (\~25 g) force to the bottom of the sulcus/pocket at six sites (mesiobuccal, buccal, distobuccal, mesiolingual, lingual, distolingual) on all present teeth/ implants.

    Time frame: 4th month

  12. Bleeding on probing (Ainamo & Bay 1975)

    Bleeding on probing A bleeding-on-probing percentage score assessed as the proportion of bleeding sites (dichotomous yes/no evaluation) when stimulated by a standardized manual probe with a controlled (\~25 g) force to the bottom of the sulcus/pocket at six sites (mesiobuccal, buccal, distobuccal, mesiolingual, lingual, distolingual) on all present teeth/ implants.

    Time frame: 7th month

  13. Keratinized mucosa width

    The apical-coronal distance from the mucosal margin to the mucogingival junction (MGJ) Measurements will be made at three points on implants (mesiobuccal, midbuccal, distobuccal) using a periodontal probe.

    Time frame: Baseline (prior to therapy)

  14. Keratinized mucosa width

    The apical-coronal distance from the mucosal margin to the mucogingival junction (MGJ). Measurements will be made at three points on implants (mesiobuccal, midbuccal, distobuccal) using a periodontal probe.

    Time frame: 1st month

  15. Keratinized mucosa width

    The apical-coronal distance from the mucosal margin to the mucogingival junction (MGJ). Measurements will be made at three points on implants (mesiobuccal, midbuccal, distobuccal) using a periodontal probe.

    Time frame: 4th month

  16. Keratinized mucosa width

    The apical-coronal distance from the mucosal margin to the mucogingival junction (MGJ). Measurements will be made at three points on implants (mesiobuccal, midbuccal, distobuccal) using a periodontal probe.

    Time frame: 7th month

  17. Probing depth

    Probing pocket depth: The distance from the base of the pocket to the mucosal margin. Measurements will be made at six points on all teeth/ implants (mesiobuccal, midbuccal, distobuccal, mesiolingual, midlingual, and distolingual) using a periodontal probe.

    Time frame: Baseline (prior to therapy)

  18. Probing depth

    Probing pocket depth: The distance from the base of the pocket to the mucosal margin. Measurements will be made at six points on all teeth/ implants (mesiobuccal, midbuccal, distobuccal, mesiolingual, midlingual, and distolingual) using a periodontal probe.

    Time frame: 1st month

  19. Probing depth

    The distance from the base of the pocket to the mucosal margin. Measurements will be made at six points on all teeth/ implants (mesiobuccal, midbuccal, distobuccal, mesiolingual, midlingual, and distolingual) using a periodontal probe.

    Time frame: 4th month

  20. Probing depth

    The distance from the base of the pocket to the mucosal margin. Measurements will be made at six points on all teeth/ implants (mesiobuccal, midbuccal, distobuccal, mesiolingual, midlingual, and distolingual) using a periodontal probe.

    Time frame: 7th month

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Dec 2026, 32 months after the start.

Of 67 non-industry interventional studies with no phase under Mucositis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 26. This study's planned 32 months is above that.

Counting every sponsor, half of 70 studies reached it within 12 months; a quarter within 6 and three quarters within 26.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 19, 2026: primary completion Sep 2026 → Dec 2026 and completion Sep 2026 → Jan 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2024
First posted
Mar 12, 2024
StartActual
Mar 27, 2024
Primary completionEst.
Dec 10, 2026was Sep 2026
CompletionEst.
Jan 10, 2027was Sep 2026
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 10, 2026→Dec 10, 2026
Nov 19, 2026
Study completion
Sep 10, 2026→Jan 10, 2027
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Primary completion Sep 10, 2026→Dec 10, 2026
    Study completion Sep 10, 2026→Jan 10, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06305000
Lead sponsor
Biruni University
Responsible party
Ayse Ege SELMAN (Principle Investigator, Biruni University) — Principal investigator
First posted
Mar 12, 2024
Start date
Mar 27, 2024
Primary completion
Dec 10, 2026 (estimated)
Completion
Jan 10, 2027 (estimated)
Last update
Nov 19, 2026

Study contacts

Ayse E Selman
Contact
aselman@biruni.edu.tr
+905366393184
Ayse E Selman
principal investigator · Biruni University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion